Trimodality therapy for bladder cancer: modern management and future directions

Curr Opin Urol. 2019 May;29(3):210-215. doi: 10.1097/MOU.0000000000000601.

Abstract

Purpose of review: This review examines both trimodality therapy (TMT) in the definitive management of bladder cancer as well as the use of adjuvant radiotherapy for bladder cancer with a specific focus on publications from the last 2 years.

Recent findings: TMT is an effective management strategy for muscle invasive bladder cancer with outcomes similar to radical cystectomy. Effectiveness of this strategy exists in variant histologies and can be personalized with use of biomarkers. There is a role for adjuvant radiotherapy in locally advanced bladder cancer, especially in the age of improved imaging and modern radiotherapy techniques.

Summary: This review should provide the reader data necessary to support use of TMT and adjuvant radiation therapy in their clinic.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Cystectomy
  • Humans
  • Immunotherapy
  • Neoplasm Invasiveness
  • Organ Sparing Treatments
  • Radiotherapy, Adjuvant
  • Treatment Outcome
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery
  • Urinary Bladder Neoplasms / therapy*